ORTX — Orchard Therapeutics Share News
0.000.00%
Last trade - 00:00- $378.06m
- $278.24m
- $22.66m
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln
Notice Regarding Agreement To Acquire Shares Of Uk Biopharmaceutical Company Orchard Therapeutics PLC
Brief: Orchard Therapeutics U.S. FDA Accepted Filing Of BLA For Otl-200 In Metachromatic Leukodystrophy Under Priority Review
Brief: Orchard Therapeutics Announces Acceptance Of Biologics License Application For Otl-200 In Mld, Receives Priority Review
Brief: Orchard Therapeutics Completes Submission Of Biologics License Application For OTL-200 In MLD To U.S. FDA
Brief: Orchard Therapeutics Announces Positive Clinical And Preclinical Data In Programs Targeting Neurometabolic And Cns Disorders At Asgct
Brief: Orchard Therapeutics Reports First Quarter 2023 Financial Results
Brief: Orchard Therapeutics Announces New Clinical And Pre-Clinical Data At ASGCT 2023
Brief: Orchard Therapeutics- On March 24, 2023, Received Letter From Nasdaq Notifying It Had Regained Compliance With Nasdaq’S Minimum Bid Price Requirement
Brief: Deep Track Capital, LP Reports About 10% Passive Stake In Orchard Therapeutics PLC Ordinary Shares As Of March 10 - SEC Filing
Orchard Therapeutics jumps on FDA nod for human trials of genetic disease therapy
Brief: Orchard Therapeutics, Pharming Group Announce Collaboration To Develop And Commercialize Ex Vivo Autologous HSC Gene Therapy For Hereditary Angioedema
U.S. RESEARCH ROUNDUP-Ceridian HCM Holding, Norwegian Cruise Line Holdings, Royal Caribbean Group
Brief: Orchard Therapeutics Announces Regulatory And Clinical Updates For Lead Gene Therapy Programs
Brief: Orchard Therapeutics Says Notified Ucl Business & Regents Of Ucla That Co Was Terminating License Relating Co's Otl-101 Program For Ada-Scid
Orchard Therapeutics PLC reports results for the quarter ended in March - Earnings Summary